https://www.selleckchem.com/pr....oducts/cetuximab.htm
However, compared with the placebo group, patients in the PG group showed a lower incidence of subclinical heart failure (21.9% vs 8.2%, respectively, P = .033), as well as lower cardiac troponin T levels (48.4% vs 31.1%, respectively, P = .002). Importantly, there were no differences observed in the antitumor effects of anthracycline between the 2 groups (disease-free survival hazards ratio = 1.09, 95% confidence interval = 0.45-2.62, P = .84; overall survival hazards ratio = 1.46, 95% confidence interval = 0.33-6.43, P = .62). Concl
Like
Comment
Share
